Highlights and Quick Summary
- Net Debt/EBITDA for the quarter ending June 29, 2021 was 4.55 (a -19.3% decrease compared to previous quarter)
- Year-over-year quarterly Net Debt/EBITDA decreased by -16.14%
- Annual Net Debt/EBITDA for 2020 was 1.9 (a -76.41% decrease from previous year)
- Annual Net Debt/EBITDA for 2019 was 8.06 (a -1022.19% decrease from previous year)
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.
Historical Net Debt/EBITDA of Phathom Pharmaceuticals, Inc.Most recent Net Debt/EBITDAof PHAT including historical data for past 10 years.
Interactive Chart of Net Debt/EBITDA of Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc. Net Debt/EBITDA for the past 10 Years (both Annual and Quarterly)
Business Profile of Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.